{"id":"leo-90100-foam","safety":{"commonSideEffects":[{"rate":null,"effect":"Application site irritation"},{"rate":null,"effect":"Skin atrophy"},{"rate":null,"effect":"Folliculitis"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"LEO 90100 is a potent topical corticosteroid delivered in a foam vehicle that improves drug delivery to affected skin areas. The foam formulation enhances spreadability and penetration while reducing systemic absorption compared to traditional formulations. It works by suppressing inflammatory responses and immune activity in the skin.","oneSentence":"LEO 90100 foam is a topical corticosteroid formulation designed for enhanced skin penetration and anti-inflammatory effects in dermatological conditions.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:49:22.024Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Inflammatory skin conditions (psoriasis, atopic dermatitis, or other dermatitis)"}]},"trialDetails":[{"nctId":"NCT05919082","phase":"PHASE3","title":"A Study to Investigate Efficacy and Safety With LEO 90100 Compared With Daivobet® Ointment in Adult Chinese Subjects With Stable Plaque Psoriasis","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2023-06-21","conditions":"Stable Plaque Psoriasis","enrollment":604},{"nctId":"NCT03806790","phase":"PHASE3","title":"Efficacy and Safety of LEO 90100 Foam in Japanese Subjects With Psoriasis Vulgaris","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2019-01-24","conditions":"Psoriasis Vulgaris","enrollment":182},{"nctId":"NCT01866163","phase":"PHASE3","title":"LEO 90100 Compared to Vehicle in Subjects With Psoriasis Vulgaris","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2013-06","conditions":"Psoriasis Vulgaris","enrollment":426},{"nctId":"NCT02132936","phase":"PHASE3","title":"LEO 90100 Aerosol Foam Compared to Calcipotriol Plus Betamethasone Dipropionate Gel in Subjects With Psoriasis Vulgaris","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2014-06","conditions":"Psoriasis Vulgaris","enrollment":504},{"nctId":"NCT02387853","phase":"PHASE2","title":"Safety and Efficacy of Once Daily Topical Treatment With LEO 90100 Aerosol Foam in Adolescent Subjects With Plaque Psoriasis","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2016-03","conditions":"Psoriasis Vulgaris","enrollment":117},{"nctId":"NCT02310646","phase":"PHASE3","title":"Patient Insights Following Use of LEO 90100 Aerosol Foam and Daivobet® Gel in Subjects With Psoriasis Vulgaris","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2015-01","conditions":"Psoriasis Vulgaris","enrollment":219},{"nctId":"NCT02518048","phase":"PHASE2","title":"A Psoriasis Plaque Test Trial With LEO 90100 Compared to Betesil® in Patients With Psoriasis Vulgaris","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2015-08","conditions":"Skin and Connective Tissue Diseases","enrollment":35},{"nctId":"NCT01536886","phase":"PHASE2","title":"LEO 90100 Compared With Calcipotriol Plus Betamethasone Dipropionate Ointment, LEO 90100 Vehicle and Ointment Vehicle in Subjects With Psoriasis Vulgaris","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2012-05","conditions":"Psoriasis Vulgaris","enrollment":376},{"nctId":"NCT01536938","phase":"PHASE2","title":"LEO 90100 in the Treatment of Psoriasis Vulgaris","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2012-05","conditions":"Psoriasis Vulgaris","enrollment":303},{"nctId":"NCT02416258","phase":"PHASE2","title":"A Psoriasis Plaque Test Trial With LP0113 Spray in Patients With Psoriasis Vulgaris (LP0113-1123)","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2015-04","conditions":"Skin and Connective Tissue Diseases","enrollment":50},{"nctId":"NCT01946386","phase":"PHASE1","title":"A Vasoconstriction Study With LEO 90100","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2013-09","conditions":"Psoriasis Vulgaris","enrollment":35},{"nctId":"NCT03442244","phase":"PHASE1","title":"Skin Irritation of LEO 90100 Foam (Calcipotriol Hydrate Plus Betamethasone Dipropionate) in Healthy Japanese Subjects","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2018-01-30","conditions":"Psoriasis Vulgaris","enrollment":20},{"nctId":"NCT03476746","phase":"PHASE1","title":"Dermatopharmacokinetic Trial of LEO 90100 Foam","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2018-03-20","conditions":"Healthy","enrollment":58},{"nctId":"NCT02899962","phase":"PHASE3","title":"LEO 90100 Twice Weekly Maintenance Regimen for Psoriasis Vulgaris","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2017-02-15","conditions":"Psoriasis Vulgaris","enrollment":722},{"nctId":"NCT02973776","phase":"PHASE1","title":"Vasoconstriction Trial With LEO 90100 Aerosol Foam","status":"COMPLETED","sponsor":"LEO Pharma","startDate":"2016-12","conditions":"Psoriasis Vulgaris","enrollment":36}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Enstilar® Foam"],"phase":"phase_3","status":"active","brandName":"LEO 90100 foam","genericName":"LEO 90100 foam","companyName":"LEO Pharma","companyId":"leo-pharma","modality":"Small molecule","firstApprovalDate":"","aiSummary":"LEO 90100 foam is a topical corticosteroid formulation designed for enhanced skin penetration and anti-inflammatory effects in dermatological conditions. Used for Inflammatory skin conditions (psoriasis, atopic dermatitis, or other dermatitis).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":3,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}